ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection.[1][2]
History
The research was done at Georgia State University and the Paul Ehrlich Institute.[3]
See also
References
- ^ White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, et al. (July 2007). "Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–2303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.
- ^ Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, et al. (April 2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMC 4080709. PMID 24739760.
- ^ Grush L (2015-03-24). "New oral drug can stop measles infection before symptoms begin". Fox News. Retrieved 2020-11-18.